Chemical ablation device for treating arrhythmia

Abstract

The invention relates to a chemical ablation device for treating arrhythmia, and in particular relates to an ablation device for ablating a cardiac muscle tissue through a chemical reagent and verifying an ablation effect. The chemical ablation device for treating the arrhythmia comprises a tongs body, a tongs head consisting of a pair of tongs hooks, a needle head assembly, a needle head expansion and retraction control assembly, a pipeline component and an electrocardiographic mapping component. According to the chemical ablation device, a needle head can be controlled to extend out or be retracted into the tongs head through the needle head expansion and retraction control assembly; a chemical ablation reagent is injected to the cardiac muscle tissue so as to conveniently realize complete ablation of the cardiac muscle tissue by applying a chemical ablation method, and the ablation effect can be verified through an electrocardiographic mapping system; the success rate of the arrhythmia ablation operation is increased, and the operation difficulty is reduced; and meanwhile, the manufacturing cost of the ablation device and assorted equipment is reduced, and the expenses for atrial fibrillation surgical operation are substantially reduced.

Description

technical field [0001] The invention relates to a surgical instrument for treating and mapping arrhythmia, in particular to a chemical ablation device for ablation of myocardial tissue through chemical methods. Background technique [0002] Arrhythmia is a series of diseases in which the heart loses its inherent rhythm due to various reasons, and its incidence rate is high and it is extremely harmful to health. For example, the most common clinical sustained arrhythmia is called atrial fibrillation (abbreviated as atrial fibrillation). It is caused by various pathogenic factors that lead to abnormal changes in the electrophysiological properties of atrial myocytes, causing rapid and irregular contractions of the atria and ventricles. As a result, patients will have symptoms such as palpitations, shortness of breath, and fatigue, and increase the incidence of adverse events such as heart failure, thromboembolism, and death. At present, the total prevalence rate of atrial fib...

AI Technical Summary

Problems solved by technology

[0004] However, the bipolar radiofrequency ablation forceps currently used in surgical operations can ablate the atrial tissue at the electrode contact position on the jaws after being clamped on the vestibule of the pulmonary veins, but between the opening of the jaws and the bottom of the jaws on both sides During the period, some atrial tissue could not contact the electrode, so that the continuous and complete ablation of the pulmonary vein vestibule could not be achieved, and there was a potential basis for the appearance of an electrical isolation "gap" after radiofrequency ablation and new atrial arrhythmias

The existing bipolar radiofrequency ablation forceps are attached to the epicardium to release radiofrequency energy, which makes it difficult to form transmural damage to the thicker ventricular wall, so the therapeutic effect on ventricular arrhythmia is minimal

Moreover, the existing bipolar radiofrequency ablation forceps cannot map whether the ablation site forms a continuous and complete ablation diameter line or whether there is a gap after the ablation is completed, so that the surgical effect cannot be verified during the operation, leaving a certain possibility for the recurrence of arrhythmia. Hidden danger

In addition, the currently used bipolar radiofrequency ablation forceps are all imported, complex in structure, expensive to manufacture, and require a series of supporting equipment such as radiofrequency energy generators, which makes the surgical treatment of atrial fibrillation expensive, and makes it impossible for some hospitals to carry out this procedure. treat

[0005] Chinese invention patent 201110429592.5 discloses a chemical ablation device for treating atrial fibrillation, but in actual operation, when the ablation forceps are placed and clamped on the target ablation site, the injection needles on the ablation forceps may damage the surrounding tissue , and even damage the atrium or pulmonary vein wall, causing bleeding

In addition, the chemical ablation device did not verify the ablation effect

Images